Searched for
EYECYTE RPE
Eyestem receives CDSCO approval to initiate Phase 2 randomised, controlled human trials of Eyecyte-RPEEyestem Research has secured approval from India's CDSCO to begin Phase 2 clinical trials for its Eyecyte-RPE cell therapy. This treatment ...- Eyestem’s Eyecyte-RPE trial shows vision rescue for geographic atrophy patientsEyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy Innovation Summit in ...
- Eyestem completes first set of patient injections for Dry AMD treatmentEyestem Research has completed the first set of patient injections for its RPE suspension therapy aimed at treating Dry age-related macular...
- Eyestem to begin human trials for its pioneering Dry AMD treatmentDry AMD, a leading cause of vision loss in the ageing population of people over 50, has long been a challenge due to the limited availabili...
- Advancing stem cell therapy: The regulatory process to get to clinical trialsAdvancements in new drug and stem cell therapy can transform the treatment of many diseases, but development is complicated, takes years an...
- Eyestem partners with RetinAI for treatment of geographic atrophy with AI techGeographic atrophy can lead to irreversible loss of vision over time and currently affects 200 million people globally.
- Eyestem files for IND approval for its product to treat geographic atrophyEyestem Research has announced the submission of IND application to CDSCO to start first in-human trials of Eyecyte-RPE™for subjects.
- Eyestem announces US operations with appointment of Ravi Achar and engagement of Stradling advisorsEyestem has appointed Ravi Achar as Head- North America Strategy and also engaged Stradling Yocca Carlson & Rauth as its US law firm.
- ET Startup Awards 2022: Eyestem bags the Top Innovator awardEyestem’s aim to treat “incurable” eye diseases helped it pip Haber, an artificial intelligence powered startup that simplifies manufacturi...
- ET Startup Awards 2022: Nominees for Top InnovatorThe award will recognise innovations that launch a business or give it a big boost. It should be an original idea that is core to the busin...
- Eyestem raises Series A round from Biological E, Alkem and othersThe investment will enable Eyestem to progress a treatment for Dry Age-related Macular Degeneration to the clinic.
- Cell therapy startup Eyestem raises ₹51 crore from BE, Alkem & NatcoExisting investors Endiya Partners and Kotak Private Equity also participated in this round, valuing Eyestem at $46.4 million (INR 371 Cror...
- Eyestem has a visionary approach to make cell therapy affordable in IndiaCell and gene therapy can go a long way in treating incurable diseases, but currently it is very pricey. Eyestem wants to dramatically cut ...
Load More
